- PharmAla Biotech (CSE:MDMA) has been contracted as a supplier of MDMA to a clinical trial at Harvard’s Maclean Hospital
- The largest neuroscientific and psychiatric private research hospital in the world, McLean is ranked 1st among all psychiatric hospitals in the United States according to U.S. News & World Report
- The Toronto-based company stated that researchers can access a new tool, which provides drug product quality information that researchers can examine directly
- PharmAla Biotech Holdings Inc. stock opened trading at $0.085 per share
PharmAla Biotech (CSE:MDMA) has been contracted as a supplier of MDMA to a clinical trial at Harvard’s Maclean Hospital.
“PharmAla has received numerous clinical trial inquiries and leads from key research organizations,” Nicholas Kadysh, CEO of PharmAla Biotech, said in a news release. “We look forward to improving the lives of patients by providing high-quality MDMA to researchers in the U.S. We’re also exploring mechanisms to pre-position some of our research materials in the U.S., in order to simplify our supply chain for these U.S. trials.”
The Toronto-based company stated that researchers can access a new tool, which provides drug product quality information that researchers can examine directly. The team is confident it can offer research customers rapid support to convert their clinical trial registrations and IRB approvals to the LaNeo MDMA chemistry, manufacturing and control package.
The largest neuroscientific and psychiatric private research hospital in the world, McLean is differentiated from its peers by its combination of teaching, treatment and research, while most other facilities focus on only one. It is ranked first among all psychiatric hospitals in the United States according to U.S. News & World Report.
This development comes less than a month after PharmAla was contracted to be a supplier of MDMA to a clinical trial at Johns Hopkins Medicine.
PharmAla Biotech is a biotechnology company focused on the research, development and manufacturing of MDXX-class molecules, including MDMA.
PharmAla Biotech Holdings Inc. stock (CSE:MDMA) opened trading more than 13 per cent higher at $0.085 per share, but has fallen nearly 40 per cent since the year began.
Join the discussion: Find out what everybody’s saying about this stock on the PharmAla Biotech Holdings Inc. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image: PharmAla Biotech)